Overview

Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression

Status:
Withdrawn

Trial end date:
2010-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess feasibility and safety of using once daily Fondaparinux Sodium (ARIXTRA®) in patients with ovarian cancer who are in 'clinical remission' (no clinical evidence of disease) after chemotherapy but at high risk of ovarian cancer recurrence.

Phase:

Phase 1

Details

Lead Sponsor:

New York University School of Medicine
NYU Langone Health

Collaborator:

GlaxoSmithKline

Treatments:

Fondaparinux
PENTA